Canadian biopharmaceutical company Find Therapeutics has dosed the first subject in a Phase I trial of its lead compound, FTX-101, as a potential treatment for chronic optic neuropathy.
The company received approval for the two-part trial from the US Food and Drug Administration earlier this year.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Part I is a double-blind, randomised, placebo-controlled, single-ascending dose (SAD) study enrolling 40 subjects, while the second part is a multiple-ascending dose (MAD) study that will enrol 24 subjects.
The study aims to evaluate the safety, tolerability and pharmacokinetics of FTX-101 versus placebo in healthy volunteers.
Find Therapeutics expects to release data from the trial in the first half of next year.
FTX-101 is designed as a remyelinating agent that could restore vision for individuals suffering from chronic optic neuropathy, a condition resulting from demyelination in the visual pathways.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe therapeutic peptide modulates the Plexin A1 / Neuropilin 1 receptor complex in the brain to promote remyelination.
Preclinical data have shown that FTX-101 demonstrates strong myelin repair activity.
Find Therapeutics CEO Philippe Douville said: “The initiation of this study is a significant milestone for both our company and individuals who suffer from chronic optic neuropathy.
“In this study, we will build on the large body of preclinical evidence demonstrating FTX-101’s effects in models of autoimmune disease.
“A therapy of this type would represent a major step forward in finding the first treatment to improve the lives of people afflicted with chronic optic neuropathy.”
Founded in 2020, Find Therapeutics aims to develop next-generation therapies for inflammatory autoimmune diseases.
The company has been supported by CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec, as well as SATT-Conectus and the University of Strasbourg.
Last month, it raised C$11m ($8.1m) in a convertible note financing round held to advance FTX-101 into Phase I clinical studies.
